Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Adj EPS $2.04 VS. $1.46 Y/Y -Rev. $12.97B, (est $11.74B) - Sees FY Adj EPS $6.75 To $7, Saw $6.05 To $6.35 (est $6.33) - Sees FY Rev. About $498 To $50B, Saw About $468 To $47.5B - Still Sees FY Adj Gross Margin About 69% To 70%, Est. 69.5%
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
() -- Bristol-Myers Squibb (BMY) is expected to boast a "solid" Q2 in line with expectations on revenue and earnings ahead of what is expected to be a "pivotal" H2, RBC Capital Markets said in note Friday. RBC noted a lack of "idiosyncrasies" in the company's Q2. "It's encouraging to see Bristol-Myers Squibb continue t